Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
49mon MSN
Q4 2024 Management View CEO Chris Boerner highlighted a robust performance in Q4 2024, driven by double-digit growth in the company’s growth portfolio, including key products like Breyanzi, Camzyos, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback